CALL/ROCHE GS/400/0.1/20.12.24 Share Price

Warrant

DE000GZ696Y9

Market Closed - BOERSE MUENCHEN 19:25:41 23/05/2024 BST
0.02 EUR 0.00% Intraday chart for CALL/ROCHE GS/400/0.1/20.12.24
Current month-37.50%
1 month-31.03%
Date Price Change
23/05/24 0.02 0.00%
22/05/24 0.02 -13.04%
21/05/24 0.023 -8.00%
17/05/24 0.025 0.00%
16/05/24 0.025 +31.58%

Real-time BOERSE MUENCHEN

Last update May 23, 2024 at 07:25 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GZ696Y
ISINDE000GZ696Y9
Date issued 28/12/2022
Strike 400 CHF
Maturity 20/12/2024 (211 Days)
Parity 10 : 1
Emission price 0.36
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.52
Lowest since issue 0.012
Delta0.03x
Omega 10.50
Premium72.64x
Gearing335.35x
Moneyness 0.5803
Difference Strike 167.9 CHF
Difference Strike %+41.98%
Spread 0.1
Spread %83.33%
Theoretical value 0.0680
Implied Volatility 35.09 %
Total Loss Probability 98.38 %
Intrinsic value 0.000000
Present value 0.0680
Break even 400.67 €
Theta-0.01x
Vega0.01x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
232.1 CHF
Average target price
279.8 CHF
Spread / Average Target
+20.57%
Consensus